Skip to main content

Table 1 In vitro susceptibility pattern of MBL producing and non-MBL-producing isolates of E. coli and K. pneumoniae by disc diffusion test

From: Incidence of metallo-beta-lactamase producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in central Nepal

Antibiotics tested % sensitive
E. coli (n = 216) K. pneumoniae (n = 185)
Non-MBL producer (n = 175) MBL producer (n = 41) Non-MBL producer (n = 146) MBL producers (n = 39)
Ampicillin (10 μg) 2.85 0.00 0.00 0.00
Cephalothin (30 μg) 16.57 0.00 13.69 0.00
Cefpodoxime (10 μg) 35.42 0.00 33.56 0.00
Ceftazidime (30 μg) 40.57 0.00 37.67 0.00
Cefotaxime (30 μg) 38.85 0.00 39.72 0.00
Ceftriaxone (30 μg) 43.42 0.00 42.46 0.00
Cefepime (30 μg) 46.85 0.00 44.52 0.00
Aztreonam (30 μg) 40.0 0.00 41.09 0.00
Cefoxitin (30 μg) 64.57 0.00 69.18 0.00
Piperacillin/tazobactam (100/10 μg) 82.85 0.00 77.39 0.00
Imipenem (10 μg) 100.00 0.00 100.00 0.00
Meropenem (10 μg) 100.00 0.00 100.00 0.00
Ertapenem (10 μg) 100.00 0.00 100.00 0.00
Ciprofloxacin (5 μg) 64.00 7.31 67.12 10.25
Levofloxacin (5 μg) 85.14 24.39 87.67 28.20
Co-Trimoxazole 61.14 0.00 65.75 7.69
Gentamicin (10 μg) 72.57 17.07 70.54 15.38
Amikacin (30 μg) 80.57 21.95 78.08 20.51
Tigecycline (15 μg) 100.00 100.00 100.00 100.00
Colistin (10 μg) 100.00 100.00 100.00 100.00